{"text": "bmy phase 3 trial evaluating lisocabtagene maraleucel in second line relapsed or refractory large b cell lymphoma shows positive topline results via"}
{"text": "before bmy 650m upfront 2 45b milestone for esaly fra adc deal mrk licensed endocyte fra smdc with intention for 6 tumor types beyond oc for then high 120m upfront 880m milestone in 2012 this deal signal bmy intention beyond oc again imgn stro"}
{"text": "urnm bmy fez urnm ewk ewo cve su"}
{"text": "short sale volume not short interest for cris at 2021 06 17 is 43 pfe 44 mdgl 35 bmy 42 ebs 38"}
{"text": "bristol myers onureg scores european approval as maintenance therapy for acute myeloid leukemia bmy"}
{"text": "oplagtri is in the process of being trademarked by bristol myers squibb company oplagtri bmy bmy bmy ri bmymp celg ri"}
